新型药物时代新诊断多发性骨髓瘤患者中t(4;14)易位的预后价值

Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.

作者信息

Geng Chuanying, Yang Guangzhong, Zhou Huixing, Wang Huijuan, Li Yanchen, Leng Yun, Zhang Zhiyao, Jian Yuan, Chen Wenming

机构信息

Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.

出版信息

Hematology. 2023 Dec;28(1):2161222. doi: 10.1080/16078454.2022.2161222.

DOI:10.1080/16078454.2022.2161222

PMID:36607148

Abstract

OBJECTIVE

To evaluate the prognostic value of t(4; 14) translocation for newly diagnosed multiple myeloma (MM) patients in the novel agent era.

METHODS

We retrospectively analyzed 606 newly diagnosed MM patients treated with novel agents. The propensity score matching technique was used to reduce the bias between groups.

RESULTS

Among 606 patients, t(4; 14) was observed in 108 (17.8%) patients, among which 79 (73.1%) were accompanied by 1q21 gain and/or del 17p. Median overall survival (OS) (56.2 vs. 87.3 months) and progression-free survival (PFS) (25.7 vs. 37.6 months) were significantly shorter in patients with t(4;14) compared with patients without cytogenetic abnormalities. Univariate Cox proportional hazards regression analysis showed that the t(4;14) was not associated with shorter OS ( = 0.666) and PFS ( = 0.164). The multivariable analysis also showed t(4;14) was not a poor prognostic factor for OS and PFS of patients with newly diagnosed MM ( > 0.05). After balancing the distribution of factors between patients with and without t(4;14) by the propensity score matching technique, patients with t(4;14) had similar OS (57.6 vs. 56.5 months, = 0.964) and PFS (26.5 vs. 28.1 months, = 0.740) with the patients without t(4;14).

CONCLUSIONS

These results demonstrated that t(4; 14) alone may be not a poor prognostic factor patients with newly diagnosed MM in the novel agent era.

摘要

目的

评估t(4;14)易位对新型药物时代新诊断的多发性骨髓瘤（MM）患者的预后价值。

方法

我们回顾性分析了606例接受新型药物治疗的新诊断MM患者。采用倾向评分匹配技术以减少组间偏差。

结果

在606例患者中，108例（17.8%）观察到t(4;14)，其中79例（73.1%）伴有1q21增益和/或17p缺失。与无细胞遗传学异常的患者相比，t(4;14)患者的中位总生存期（OS）（56.2个月对87.3个月）和无进展生存期（PFS）（25.7个月对37.6个月）显著更短。单因素Cox比例风险回归分析显示，t(4;14)与较短的OS（=0.666）和PFS（=0.164）无关。多变量分析也显示，t(4;14)不是新诊断MM患者OS和PFS的不良预后因素（>0.05）。通过倾向评分匹配技术平衡有和无t(4;14)患者之间的因素分布后，有t(4;14)的患者与无t(4;14)的患者具有相似的OS（57.6个月对56.5个月，=0.964）和PFS（26.5个月对28.1个月，=0.740）。